Antiinflammatory therapy with canakinumab for atherosclerotic disease.
New England Journal of Medicine.
Times cited: 1605
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
American Heart Journal.
Times cited: 63